Natalizumab: Benefit outweighs risk in selected patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 1, Issue 3, 2008, Pages 151-153

  Phillips, J Theodore ^a   Frohman, Elliot M ^b  

^a Multiple Sclerosis Treatment Center of Dallas   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993790660     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285608099124     Document Type: Editorial

References (12)

1. Balcer, L.J., Galetta, S.L., Calabresi, P.A., Confavreux, C., Giovannoni, G., Havrdova, E. et al. (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299-1304.
2. Frohman, E.M., Stuve, O., Havrdova, E., Corboy, J., Achiron, A., Zivadinov, R. et al. (2005) Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol 62: 1519-1530.
3. Goodin, D.S., Frohman, E.M., GarmanyJr, G.P., Halper, J., Likosky, W.H., Lublin, F.D. et al. (2002) Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the Ms Council for Clinical Practice Guidelines. Neurology 58: 169-178.
4. Kappos, L., Bates, D., Hartung, H.P., Havrdova, E., Miller, D., Polman, C.H. et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6: 431-441.
5. Khatri, B., Fox, R., Koo, A.P., Lynn, F., Duda, P., Jurgensen, S. et al. (2008) Plasma exchange accelerates the decline of serum natalizumab concentration in patients with multiple sclerosis: results of the Natalizumab PLEX study. Neurology 70: A227-A228.
6. Phillips, J.T., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 67: 1717-1718.
7. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
8. Rudick, R.A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P.A., Confavreux, C. et al. (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62: 335-346.
9. Stuve, O., Marra, C.M., Bar-or, A., Niino, M., Cravens, P.D., Cepok, S. et al. (2006 a) Altered CD4+/ CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63: 1383-1387.
10. Stuve, O., Marra, C.M., Jerome, K.R., Cook, L., Cravens, P.D., Cepok, S. et al. (2006 b) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59: 743-747.
11. Thompson, J.P., Noyes, K., Dorsey, E.R., Schwid, S.R. and Holloway, R.G. (2008) Quantitative risk-benefit analysis of natalizumab. Neurology 71: 357-364.
12. Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933.